The Company will present 54 abstracts at the meeting, taking place virtually from
In addition, data will be presented on the efficacy profile of evobrutinib, an investigational, oral, highly selective Bruton's Tyrosine Kinase inhibitor (BTKi), through 108 weeks of treatment in the Phase II open-label extension (OLE) in adult patients with relapsing multiple sclerosis (RMS). Preclinical data will also be presented providing insights into evobrutinib's potential impact on progression in MS.
'The broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives,' said
Key MAVENCLAD (cladribine) tablets data include: Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined unique active (CUA) lesion count in the first six months of MAVENCLAD treatment for highly active RMS
New data evaluating cumulative relapse incidence over five years in patients enrolled in the MAVENCLAD CLARITY and CLARITY Extension trials
Late-breaking interim data from the CLASSIC-MS study on the long-term efficacy and real-world treatment patterns for patients receiving MAVENCLAD, with eight to 14 years of follow up, will be available as part of the late-breaker sessions from
Results from a post hoc analysis from the CLARITY Extension and the impact of MAVENCLAD on the prevalence of disability improvement over five years, as measured by the Expanded Disability Status Scale (EDSS)
Results from the MAGNIFY and CLARIFY studies regarding clinical outcomes in patients with COVID-19 infection during these Phase IV studies of MAVENCLAD for the treatment of MS will be available as part of the late-breaker sessions from
Updated post-approval safety data of MAVENCLAD in the treatment of MS, including respiratory viral infections and findings that the safety profile was consistent with that from the clinical development program
Key Rebif (interferon beta-1a) data include: Post-approval results on the safety of Rebif in the treatment of MS, showing no new safety signals
Key evobrutinib data include: Efficacy results of the Phase II OLE in patients treated with evobrutinib 75 mg BID (twice a day) as measured by annualized relapse rate from Week 48 to Week 108
Safety results from the 60 week Phase II OLE
Preclinical data demonstrating evobrutinib's potential to reduce CNS compartmentalized inflammation thought to drive the progression of disability seen in MS
Additional
Two product theatres on demand throughout the congress starting from
'Multiple sclerosis patient management: update from the
'Real-world multiple sclerosis management: what can we learn from MSBase' by Dr.
Following the conclusion of MSVirtual2020,
About MAVENCLAD
MAVENCLAD, approved by the
About Rebif (interferon beta-1a)
Rebif (interferon beta-1a) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is used to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS.
About Evobrutinib
Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton's tyrosine kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases. Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
For more than 20 years,
About
Contact:
Tel: 1-781-206-1951
Email: emma.silva@emdserono.com
(C) 2020 Electronic News Publishing, source